Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Should patients with epilepsy be vaccinated against coronavirus disease 2019? A systematic review and meta-analysis

Kan Lin,1, Huayao Huang, Shuangfang Fang, Guanyi Zheng, Kailong Fu, Nan Liu, Houwei Du

1 Department of Traditional Chinese Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
2 Department of Rehabilitation, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
3 Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
4 Institute of Clinical Neurology, Fujian Medical University, Fuzhou, Fujian, China

Article history:
Received 28 March 2022
Revised 13 June 2022
Accepted 23 June 2022
Available online 29 June 2022

Keywords:
COVID-19
Vaccines
Epilepsy
Seizure
Adverse effect

Abstract
Objective: The coronavirus disease 2019 (COVID-19) vaccination coverage, willingness, and safety profiles in patients with epilepsy remain poorly understood. We aimed to summarize the available evidence of COVID-19 vaccination coverage, willingness, and safety profiles among patients with epilepsy.

Methods: We performed a literature search in the Pubmed, EMBASE, and Cochrane Central Register database between 1 January 2020 and 30 April 2022. We included eligible studies that provided information on the COVID-19 vaccination coverage, willingness, and safety profiles among patients with epilepsy. We investigated the association between baseline characteristics of patients with epilepsy and unvaccination status using a fixed-effect model. We calculated the pooled overall willingness to be vaccinated against COVID-19. We systematically reviewed the safety profiles after COVID-19 vaccination in patients with epilepsy.

Results: Ten eligible observational studies and two case reports yielded 2589 participants with epilepsy or their caregivers. Among 2145 participants that provided the information of vaccination status, 1508 (70.3%) patients with epilepsy were not administered COVID-19 vaccine, and 58% (95%CI 40–75%) of respondents were willing to be vaccinated against COVID-19. Seizure status (active versus inactive, OR 1.84 95%CI 1.41–2.39, I² = 0%) rather than seizure type (focal versus non-focal, OR 1.22 95%CI 0.94–1.58, I² = 0%) was associated with COVID-19 unvaccination status. Vaccines were well-tolerated; epilepsy-related problems such as increase in seizure frequency and status epilepticus after COVID-19 vaccination were uncommon.

Conclusions: Our findings suggest a low COVID-19 vaccination coverage and willingness in patients with epilepsy. Vaccination against COVID-19 appears to be well-tolerated and safe in patients with epilepsy, supporting a positive outlook toward vaccination in this population.

1. Introduction
As of 30 April 2022, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had affected more than 500 million confirmed cases and over six million fatalities worldwide [1]. The increased infectivity of the delta and omicron mutations of the SARS-CoV-2 exacerbates the public panic [2,3]. Vaccines remain the most promising approach for controlling COVID-19 pandemic and reestablishing pre-pandemic routines.

Emerging COVID-19 vaccines protects from symptomatic SARS-CoV-2 infection. Neurologic complications of COVID-19 vaccines have been reported, including strokes, cranial neuropathies, peripheral neuropathies, acute disseminated encephalomyelitis, and
transverse myelitis, and acute idiopathic demyelinating polynu-
ropathy [4–12]. There are substantial concerns regarding the
potential risks after vaccination in those with preexisting neu-
rologic disorders. Epilepsy is one of the most common neurological
disorders, affecting more than 70 million people worldwide [13].
A previous study suggested that patients with epilepsy were at a
higher risk of experiencing unfavorable COVID-19 outcomes [14].
Taking into account the COVID-19 pandemic, it is urgent to know
the benefits and risks of vaccination for patients with epilepsy.
To our knowledge, lines of evidence of the COVID-19 vaccination
coverage, willingness, and safety profiles in patients with epilepsy
were limited. In this systematic review and meta-analysis, we
aimed to summarize the currently available evidence regarding
the COVID-19 vaccination coverage, willingness, or hesitancy in
patients with epilepsy. Moreover, we systematically reviewed the
safety and tolerability of COVID-19 vaccines among patients with
epilepsy.

2. Methods

This systematic review and meta-analysis was prospectively
registered in the international prospective register of systematic
reviews (PROSPERO: CRD42021293066) based on the Preferred
Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) guidelines [15]. We applied the methods that are recom-
mended in the Meta-analysis of Observational Studies in Epidemi-
ology proposal [16].

2.1. Search strategy

We conducted a literature search up to 30 April 2022 for rele-
vant publications with no language restriction in PubMed, Excerpta
Medica database (EMBASE), and Cochrane Central Register data-
base. Our search strategy included the following set of terms:
(“COVID-19” OR “coronavirus disease 2019” OR “SARS-CoV-2” OR
“nCoV” OR “severe acute respiratory syndrome coronavirus 2”)
AND (“vaccin*”) AND (“seizure” OR “epilepsy”). We also manually
screened references for additional studies. Additionally, the official
websites of the vaccine developers were also searched.

2.2. Inclusion and exclusion criteria

Eligible studies included randomized controlled trials, non-
randomized controlled trials, case-control studies, cohort studies,
case series, case-reports, and cross-sectional studies. We included
studies that provided information on the COVID-19 vaccination
status and willingness (hesitancy) toward COVID-19 vaccination
among patients with epilepsy. We applied the following exclusion
criteria: (1) Insufficient data information provided; (2) Review arti-
cles, meta-analyses, literature reviews, editorials, and comment-
taries; (3) Abstracts or posters from conference proceedings
before the full-text paper was formally published in a peer-
reviewed journal. Disagreements regarding inclusion or exclusion
criteria were settled by team discussion.

2.3. Screening and data extraction

Two trained authors (K.L. and S.F.) screened the title and
abstract of the identified publications to retrieve potentially eligi-
ble articles for a full-text review. These two authors (K.L. and S.
F.) blindly assessed study inclusion and study quality, and
extracted data on study characteristics (i.e., authors, date of pub-
lication, study design, setting, and sample size), participants’ charac-
teristics (i.e., mean/median age, gender, seizure types), inclusion
and exclusion criteria, and outcome measures using standardized
data collection sheets.

2.4. Definitions and outcomes

Active epilepsy was defined as having seizure occurrence within
the preceding year, and inactive epilepsy was defined as reaching
seizure-free status in the preceding year, regardless of whether anti-
seizure medications were administered [17]. The primary out-
come was vaccination coverage. Secondary outcomes included the
COVID-19 vaccination willingness and unwillingness. Additional
outcomes included impact of vaccination on epilepsy-related prob-
lems, and adverse effects after COVID-19 vaccination.

2.5. Assessment of publication bias and study quality assessment (Risk
of Bias)

All included literatures were evaluated using the Agency for
Healthcare Research and Quality (AHRQ) scale [18]. The AHRQ
scale is rated based on the overall score of its 11 items. For each
item, one score is awarded if the quality of the study meets the
methodological standard. A score of 0–4 indicates a high risk of
bias, 5–7 indicates a moderate risk of bias, and 8–11 indicates a
low risk of bias [19]. Publication bias tests for funnel plot asym-
metry and the Egger test were not performed due to the limited num-
ber of studies.

2.6. Statistical analysis

We summarized dichotomous primary outcome of interest as
odds ratios (ORs) using a fixed-effect model (Mantel–Haenszel
approach). We conducted a sensitivity analysis using a random-
effect model. We evaluated heterogeneity by inspecting forest
plots, and with tests for heterogeneity after calculating the Q
statistic and I² values. We considered an I² statistic threshold of
50% as a low and high heterogeneity [20]. Based on the Interna-
tional League Against Epilepsy (ILAE) criteria, seizures are classi-
ified into focal onset, generalized onset, and unknown onset.
Epilepsy is classified into four subtypes: combined generalized
and focal epilepsy, generalized epilepsy, focal epilepsies, and
unknown category [21]. To investigate the association between
the seizure type and unvaccination status, if the original study gave
epileptic classification rather than seizure classification, we added
unclassified seizure in epilepsy classification to the non-focal
group in seizure type classification. We combined the generalized
and unknown types into a group to reflect non-focal onset versus
focal onset type. We also performed a single-arm meta-analysis
to determine the pooled overall willingness and unwillingness to
be vaccinated against COVID-19. We performed a separate analysis
by excluding patients’ caregivers to investigate vaccination will-
ingness in patients with epilepsy. We did not perform the prede-
ned subgroup analysis because of the small number of included
studies. All analyses were performed using the STATA 15.0 (Stata
Corp LP, College Station, TX) and the Cochrane Collaboration’s
Review Manager (Rev Man 5.3) Software Package (2014; Nordic
Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark).
Statistical significance was set at \( \alpha = 0.05 \) for all analyses.

3. Results

3.1 Study selection

An initial literature search yielded 250 articles. After screening
82 duplicates and 152 papers through titles and abstracts, we
retrieved the full texts of the remaining 16 studies. Ten observa-
tional studies and two case report studies [17,22–32] that met
the inclusion criteria were included in this systematic review and meta-analysis (Fig. 1).

3.2. Study characteristics

Table 1 summarizes the baseline characteristics of the included studies. The sample size of eligible participants in ten observational studies ranged from 38 to 557, yielding a total of 2587 participants. No studies provided propensity score matching analysis results. Seven studies [17,23–26,29,30] provided the information of primary outcome (vaccination status), and six studies [22,24–26,28,29] reported the secondary outcomes of vaccination willingness and unwillingness. Seven studies [17,23–27,30] provided the information of primary outcome (vaccination status), and six studies [22,24–26,28,29] reported the secondary outcomes of vaccination willingness and unwillingness. Seven studies [17,23–27,30] provided the information of primary outcome (vaccination status), and six studies [22,24–26,28,29] reported the secondary outcomes of vaccination willingness and unwillingness. Seven studies [17,23–27,30] provided the information of primary outcome (vaccination status), and six studies [22,24–26,28,29] reported the secondary outcomes of vaccination willingness and unwillingness.

3.3. Association between the baseline characteristics of epilepsy and unvaccination

Supplemental Table 3 summarizes the baseline characteristics among vaccinated and unvaccinated patients. Of 2154 participants that provided the information of vaccination status, 1508 (70.3%) patients with epilepsy were not administered COVID-19 vaccines [17,23–26,29,30]. A meta-analysis showed that patients with active epilepsy were more likely to be unvaccinated than those with inactive epilepsy (OR 1.84, 95%CI 1.41–2.39, $I^2 = 0\%$, fixed-effects model, Fig. 2A). The unvaccination status was not significantly different among different seizure types (focal versus non-focal onset, OR 1.22, 95%CI 0.94–1.58, $I^2 = 0\%$, fixed-effects model, Fig. 2B) and gender (male versus female, OR 1.00, 95%CI 0.77–1.30, $I^2 = 8\%$, fixed-effects model, Fig. 2C). Sensitivity analyses using the random-effects model yielded similar results (Fig. 3).

3.4. Willingness and unwillingness to be vaccinated against COVID-19

Table 2 summarizes the COVID-19 vaccination willingness, unwillingness, or hesitancy among patients with epilepsy or their caregivers. The percentage of respondents who were willing to be vaccinated ranged from 27.59% to 94.12%. Fear of aggravating epilepsy and concern about the potential adverse effects were the most common reasons for unwillingness. Fig. 4A shows that 58% (95%CI 40–75%, random-effects models) of respondents were willing to be vaccinated against COVID-19. A sensitivity analysis by excluding their caregivers shows that 63% (95%CI 44%–80%, random-effects models) of patients with epilepsy were willing to be vaccinated against COVID-19 (Fig. 4B).

3.5. Impact of COVID-19 vaccination on epilepsy-related problems

Eight studies [17,23–27,30,31] provided information on the impact of COVID-19 vaccination on epilepsy-related problems (Supplemental Table 4). Five studies [23–25,27,30] provided information on the changes in the seizure frequency. Clayton et al. [23] showed three (20%) of patients with Dravet syndrome (a severe, early-onset, developmental, and epilepticencephalopathy)
| Study          | Country       | Research type | Setting      | Study duration       | Participants (Respondents) | Number of patients | Male n (%) | Age (y) | Seizure type classification (n)                                                                 | Epilepsy classification (n) | Epilepsy frequency (n) | Outcomes                                                                 | Vaccine platform (Number of vaccinations) |
|---------------|---------------|---------------|--------------|----------------------|----------------------------|---------------------|-------------|---------|------------------------------------------------------------------------------------------------|-----------------------------|------------------------|--------------------------------------------------------------------------|---------------------------------------------|
| Li et al. [17] | China         | Cross-sectional | Single-center | July 1 – July 21, 2021 | Patients with epilepsy | 357                  | 193 (54.1%) | 33.1    | Focal aware motor seizure (22) Focal aware nonmotor seizure (30) Focal impaired awareness motor seizure (12) Focal impaired awareness nonmotor seizure (35) Focal to bilateral tonic-clonic seizure (97) General motor seizure (6) | Not mentioned               | Active epilepsy (203)  | Vaccination status (yes or no) Adverse effects of vaccines                | Inactivated vaccine first dose (n = 38) Inactivated vaccine second dose (n = 22) |
| Asadi et al. [22] | Iran         | Single-center | Late 2020    | Patients with epilepsy | 153                       | Not mentioned       | Not mentioned | Not mentioned | Focal aware motor seizure (22) Focal aware nonmotor seizure (30) Focal impaired awareness motor seizure (12) Focal impaired awareness nonmotor seizure (35) Focal to bilateral tonic-clonic seizure (97) General motor seizure (6) | Not mentioned               | Not mentioned              | Not mentioned               | Willing to be vaccinated Adverse effects of vaccines Vaccination status (yes or no) Viral-vector vaccine first dose (n = 15) Viral-vector vaccine second dose (n = 10) |
| Clayton et al. [23] | UK           | (survey)     | Multi-center | February 2 – June, 2021 | Caregivers               | 38                   | Not mentioned | Under 5 years (n = 6) 5–11 (n = 7) 12–17 (n = 12) 18–24 (n = 5) 25–34 (n = 4) 35–44 (n = 4) | Not mentioned               | Not mentioned              | Not mentioned               | Viral-vector vaccination status (yes or no) Viral-vector vaccine first dose (n = 10) |
| Hood et al. [24] | USA/Canada   | Cross-sectional | Multi-center | May 17, 2021 – August 2, 2021 | Caregivers               | 278                  | 111 (40.0%) | <12 (n = 122) | Focal aware motor seizure (22) Focal aware nonmotor seizure (30) Focal impaired awareness motor seizure (12) Focal impaired awareness nonmotor seizure (35) Focal to bilateral tonic-clonic seizure (97) General motor seizure (6) | Not mentioned               | Not mentioned              | Not mentioned               | Vaccination status (yes or no) Adverse effects of vaccines Willing to be vaccinated mRNA vaccine (n = 115) Viral-vector vaccine (n = 5) |
| Study          | Country | Research type | Setting     | Study duration                  | Participants | Number of patients | Male n (%) | Age (y) | Seizure type classification (n) | Epilepsy classification (n) | Epilepsy frequency (n) | Outcomes                                                                 | Vaccine platform (Number of vaccinations) |
|---------------|---------|---------------|-------------|---------------------------------|--------------|--------------------|------------|---------|---------------------------------|--------------------------|----------------------|--------------------------------------------------------------------------|-----------------------------------------------|
| Lu et al. [25] | China   | Cross-sectional | Multi-center | July 24 – August 31, 2021       | Patients with epilepsy | 491               | 243 (49.5%) | 30.4    | Focal onset (245)                | Not mentioned            | Over 1 year seizure-free (145) | Vaccination status (yes or no) Adverse effects of vaccines Willing to be vaccinated | Inactivated vaccine (n = 187) Subunit vaccine (n = 14) Viral-vector vaccine (n = 2) mRNA vaccine (n = 1) |
| Massoud et al. [26] | Kuwait | Cross-sectional | Single-center | April 4, 2020 – April 18, 2021  | Patients with epilepsy | 111               | 46 (41.4%)  | 33.2    | Generalized tonic-clonic (35)   | A mean of 1.547 seizure per month | Vaccination status (yes or no) Adverse effects of vaccines Willing to be vaccinated | mRNA vaccine first dose (n = 15) mRNA vaccine second dose (n = 35) Viral-vector vaccine first dose (n = 32) |
| Özdemir et al. [27] | Turkey | Cross-sectional | Single-center | January 7 – January 9, 2021     | Patients with epilepsy | 178               | 87 (48.9%)  | 29      | Not mentioned                   | Focal epilepsy (27) Generalized epilepsy (111) Combined epilepsy (40) | Seizure free (105) | Adverse effects of vaccines mRNA vaccine (n = 136) Inactivated vaccine (n = 35) Combination (n = 7) |
| Puteikis et al. [28] | Lithuania | Cross-sectional | Single-center | December 7 – December 31, 2020  | Patients (n = 58), Caregiver (n = 53) | 111               | 44 (39.6%)  | 25      | Focal (49)                       | Generalized ("whole-body" seizures) (37) Generalized (absence or myoclonic seizures) (10) Other (10) Unknown (5) | Several times per day (17) Several times per week (14) | Willing to be vaccinated |

(continued on next page)
| Study          | Country | Research type | Setting                      | Study duration       | Participants (Respondents) | Number of patients | Male n (%) | Age (y) | Seizure type classification (n) | Epilepsy classification (n) | Epilepsy frequency | Outcomes                                      | Vaccine platform (Number of vaccinations) |
|---------------|---------|---------------|------------------------------|----------------------|---------------------------|---------------------|-------------|---------|---------------------------------|-------------------------------|-------------------|----------------------------------------------|----------------------------------------|
| Qiao et al. [29] | China   | Cross-sectional (face-to-face survey) | Multi-center               | Jun-21               | Patients with epilepsy    | 557                 | 298 (53.5%) | 42      | Focal onset (367)               | Not mentioned                | Seizure freedom (334) | Vaccination status (yes or no) Willing to be vaccinated | /                                       |
| Wrede et al. [30] | Germany | Cross-sectional (survey) | Single-center               | March 19 – April 20, 2021 | Patients with epilepsy    | 54                  | 27 (50.0%) | 47.9    | Focal (40)                      | Not mentioned               | Seizure free (11)    | Adverse effects of vaccines mRNA vaccine (n = 34) Viral-vector vaccine (n = 18) Unable to remember (n = 2) |
| Šín R et al. [31] | Czech Republic | Case report | Single-center               | /                    | Patient with well-compensated secondary epilepsy | 1                   | 1          | 56      | Not mentioned                   | Not mentioned               | No record of an epileptic seizure within the last 2 years | Adverse effects of vaccines Viral-vector vaccine (n = 1) |
| Odincova et al. [32] | Russian | Case report | Single-center               | /                    | Patient with focal pharmacoresistant epilepsy | 1                   | 1          | 59      | Not mentioned                   | Not mentioned               | 3-year seizure remission after surgical management | Adverse effects of vaccines mRNA vaccine (n = 1) |
Fig. 2. Association between the baseline characteristics of epilepsy and unvaccination status using a fixed-effect model. (A) Seizure frequency; (B) seizure type; (C) Gender.

Fig. 3. Association between the baseline characteristics of epilepsy and unvaccination status using a random-effects model. (A) Seizure frequency; (B) seizure type; (C) Gender.
| Study                  | Willingness (n) | Unwillingness or hesitancy (n) | Total (n) | Willing percentage (%) | Unwilling or hesitate percentage (%) | Factors for unwillingness (n [%]) | Factors for willingness (n [%]) |
|-----------------------|----------------|-----------------------------|-----------|-----------------------|-------------------------------------|-----------------------------------|--------------------------------|
| Li et al. [17]         | NA             | NA                          | NA        | NA                    | NA                                  | Fear of aggravating epilepsy (185 [58]) | NA                              |
|                       |                |                             |           |                       |                                     | Discouragement from health workers for epilepsy (70 [22]) | NA                              |
|                       |                |                             |           |                       |                                     | Fear of other unknown serious side effects (42 [13]) | NA                              |
|                       |                |                             |           |                       |                                     | Other diseases (12 [3.8]) | NA                              |
|                       |                |                             |           |                       |                                     | Age limit (4 [1.3]) | NA                              |
|                       |                |                             |           |                       |                                     | Breast-feeding (1 [0.3]) | NA                              |
|                       |                |                             |           |                       |                                     | Recent human papillomavirus vaccination (1 [0.3]) | NA                              |
|                       |                |                             |           |                       |                                     | Vaccine shortage (1 [0.3]) | NA                              |
|                       |                |                             |           |                       |                                     | Others (3 [0.9]) | NA                              |
| Asadi et al. [22]      | 144            | 9                           | 153       | 144 (94.12%)          | 9 (5.88%)                           | NA                                | NA                              |
| Clayton et al. [23]    | NA             | NA                          | NA        | NA                    | NA                                  | NA                                | NA                              |
| Hood et al. [24]       | 67             | 91                          | 158       | 67 (42.4%)            | 91 (57.6%)                         | Risk of increased seizures or status epilepticus (71 [78.0]) | NA                              |
|                       |                |                             |           |                       |                                     | Vaccine is not necessary (20 [32.0]) | NA                              |
|                       |                |                             |           |                       |                                     | Vaccine is not safe (41 [45.0]) | NA                              |
|                       |                |                             |           |                       |                                     | Other (27 [30.0]) | NA                              |
| Lu et al. [25]         | 171            | 116                         | 287       | 171 (59.58%)          | 116 (40.42%)                       | Worried about the potential adverse effects (153 [53.3]) | NA                              |
|                       |                |                             |           |                       |                                     | Unsatisfied with seizure/disease control (135 [47.0]) | NA                              |
|                       |                |                             |           |                       |                                     | Worried about the interaction between current medication and the vaccine (16 [3.6]) | NA                              |
|                       |                |                             |           |                       |                                     | Other comorbidity (42 [14.6]) | NA                              |
|                       |                |                             |           |                       |                                     | Local administration suggested delaying the injection (12 [4.2]) | NA                              |
|                       |                |                             |           |                       |                                     | Others (15 [5.2]) | NA                              |
| Massoud et al. [26]    | 8              | 21                          | 29        | 8 (27.59%)            | 21 (72.41%)                        | Fear of vaccine adverse events (9 [42.9]) | NA                              |
|                       |                |                             |           |                       |                                     | Fear of interaction with ASMs (4 [19.0]) | NA                              |
|                       |                |                             |           |                       |                                     | Fear of epilepsy worsening (5 [23.8]) | NA                              |
|                       |                |                             |           |                       |                                     | Already got a COVID-19 (3 [14.3]) | NA                              |
| Ozdemir et al. [27]    | NA             | NA                          | NA        | NA                    | NA                                  | Respondents thought it could cause the infection (OR = 0.14, 95% CI = 0.04–0.49) | NA                              |
| Putekis et al. [28]    | 27             | 31                          | 58        | 27 (46.55%)           | 31 (53.44%)                        | Respondents thought it could cause the infection (OR = 0.14, 95% CI = 0.04–0.49) | NA                              |
| (patient responses)    |                |                             |           |                       |                                     | Respondents thought it could cause the infection (OR = 0.14, 95% CI = 0.04–0.49) | NA                              |
|                       | 18             | 35                          | 53        | 18 (33.96%)           | 35 (66.04%)                        | Respondents thought it could cause the infection (OR = 0.14, 95% CI = 0.04–0.49) | NA                              |
| (caregiver responses)  |                |                             |           |                       |                                     | Respondents thought it could cause the infection (OR = 0.14, 95% CI = 0.04–0.49) | NA                              |

K. Lin, H. Huang, S. Fang et al. Epilepsy & Behavior 134 (2022) 108822
experienced an increase in seizure frequency after the first dose of Oxford/AstraZeneca vaccine, whereas there was no increase in seizure frequency or duration after the second dose. Hood et al. [24] showed that 11 (9%) patients with epilepsy had increased seizure after dose one, and 10 (11%) had increased seizure activity after dose two. Lu et al. [25] showed that 19 (9.3%) participants with epilepsy experienced increased seizure frequency after vaccination. Özdemir et al. [27] showed that vaccination did not affect the monthly number of seizures, and only four (2.2%) patients had more seizures than normal after vaccination. Wrede et al. [30] showed that two (3.7%) patients with epilepsy reported increased seizure frequency after COVID-19 vaccination. Changes in seizure type were reported in two studies. Lu et al. [25] reported two (1.0%) participants had a first-ever convulsive seizure. Wrede et al. [30] showed that one (1.9%) patient reported a new seizure type four days after COVID-19 vaccination. Two studies reported the occurrence of status epilepticus [26,31], both after mRNA vaccination. No occurrence of status epilepticus was reported in four studies [24,25,27,30]. Additionally, four studies [17,25,26,30] reported the outcome of seizure worsening or seizure exacerbation. However, only one study [26] provided a clear definition of seizure worsening [33] (defined as an increase in total average monthly seizure frequency, average monthly generalized tonic-clonic seizures (GTCS), new-onset GTCS, or new-onset status epilepticus). Their results showed that among 82 patients who received COVID-19 vaccination, five (6.1%) experienced seizure worsening [26]. Other three studies reported that there was no evidence of seizure exacerbation or aggravated epilepsy [17,25,30]. Generally, epilepsy-related problems after COVID-19 vaccination were uncommon.

3.6. Adverse effects after COVID-19 vaccination in patients with epilepsy

Table 3 shows that the solicited local and systemic adverse effects after COVID-19 vaccination were generally mild to moderate. Clayton et al. [23] showed that 11 (73%) patients with Dravet syndrome experienced at least one side effect after the first dose of SARS-CoV-2 vaccination, with the most common adverse effects being fatigue (40%), fever (40%), and injection site (33%). Li et al. [17] reported non-severe adverse effects after the first dose (79%) and the second dose (68%), including injection site pain, fatigue, headache, and nausea. Lu et al. [25] showed that local injection site skin adverse events and muscle pain were common after COVID-19 vaccination. Massoud et al. [26] reported the solicited local adverse effects after the first dose of COVID-19 vaccine and solicited systemic adverse effects after mRNA-based vaccination. Özdemir et al. [27] summarized the difference in side effects between two doses of mRNA vaccine (BNT162b2) and inactivated vaccine. Their data showed that patients who received BNT162b2 were more likely to experience local adverse events than those who received CoronaVac after the first and second doses ($p = 0.003$ and $p = 0.001$, respectively). Wrede et al. [30] reported different solicited systemic adverse effects after vector-based and mRNA-based vaccination. In total, no serious adverse effects or mortality were reported.

3.7. Assessment of the qualities of the studies

All included studies were survey-based cross-sectional studies, including face-to-face interview [25,29] and online survey. All included studies did not provide the information regarding the external validation of the questionnaire or survey. Table 4 shows that two studies [26,29] had a low risk of bias and eight studies [17,22–25,27,28,30] had a moderate risk of bias assessed using the AHRQ method.
4. Discussion

The present study showed a low COVID-19 vaccination coverage and willingness among patients with epilepsy. However, the uncommon incidence of epilepsy worsening after vaccination and no reports of severe COVID-19 vaccine-related adverse effects suggest that COVID-19 vaccines were safe and well-tolerated in patients with epilepsy.

Public health is under the threat of the unprecedented COVID-19 pandemic, urging the need for large-scale safe and effective vaccine coverage to achieve herd immunity. The COVID-19 vaccination coverage ranges from 10.6% to 73.9% in the included studies. The vaccine uptake rate in people with epilepsy was lower than in their same-age controls [25]. Possible reasons for the low COVID-19 vaccination coverage in patients with epilepsy might include population priority, doubts about the necessity, and availability of vaccines and vaccination services [34,35]. Moreover, our findings showed that patients with active epilepsy were more likely to be unvaccinated than those with inactive epilepsy (OR 1.84, 95%CI 1.41–2.39, $I^2 = 0\%$). However, the unvaccination status was not significantly different among different seizure types (focal versus non-focal onset, OR 1.22, 95%CI 0.94–1.58, $I^2 = 0\%$) and gender (male versus female, OR 1.00, 95%CI 0.77–1.30, $I^2 = 8\%$). The ILAE recommends vaccination for patients with epilepsy based on the low risk of increased seizure frequency after vaccination [36]. The risk of COVID-19 infection and potential complications might outweigh the risk of adverse effects caused by COVID-19 vaccine. However, different countries had different regulations to vaccination for patients with epilepsy, adapting to the local situation and culture. According to the Technical Guidelines for COVID-19 vaccination issued by the Chinese Center for Disease Control and Prevention (first edition), uncontrolled seizures are considered contraindications for vaccination in China [37]. The Chinese branch of ILAE published a Chinese consensus on the issue of COVID-19 vaccine and epilepsy in July 2021, updating that epilepsy is not a contraindication for vaccination and defining patients with six

![Fig. 4. Willingness to be vaccinated against COVID-19. (A) In patients with epilepsy and their caregivers; (B) in patients with epilepsy.](image-url)
months seizure-free could be vaccinated [38]. Nevertheless, clinicians and healthcare workers may remain cautious about vaccination for patients with active epilepsy discouraging vaccination for patients with active epilepsy.

Our analysis showed that a considerable proportion of patients with epilepsy or their caregivers were unwilling to receive COVID-19 vaccination. Notably, there is substantial heterogeneity (26.1–89.3%) regarding the unwillingness or hesitancy among included studies. For example, Asadi et al. [22] showed a low rate of vaccine hesitancy among patients with epilepsy (9 [5.9%]), which was not different from that in healthy individuals (8 [7.4%]). However, two studies [26,28] reported higher rates of vaccine hesitancy. Fear of seizure worsening, and concerns about the adverse effects and efficacy rank among the leading causes of vaccination hesitancy. Cases of seizure onset after COVID-19 vaccination [31,39,40] might influence the clinicians’ decision to recommend vaccination in patients with epilepsy. However, our analysis showed that epilepsy-related problems after COVID-19 vaccination such as increased seizure frequency and status epilepticus were uncommon in most of the included studies. For example, Lu et al. [25] showed no evidence of seizure exacerbation, and less than 10% of patients had seizure increase after COVID-19 vaccination. Özdemir et al. found that only

### Table 3
Adverse effects of COVID-19 vaccine in patients with epilepsy.

| Study                  | Vaccine platform                          | Adverse effects (frequency with percentage)                                      |
|------------------------|-------------------------------------------|---------------------------------------------------------------------------------|
| Li et al. [17]         | First dose of inactivated vaccine (n = 38)| First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                        | Second dose of inactivated vaccine (n = 22)|                                                                                         |
| Clayton et al. [23]    | viral vector and nucleic acid-based vaccines (n = 15) | First dose: No side effects (66.5%), injection site pain 2 (13.6%), injection site redness 1 (5.3%), headache 1 (5.3%), fever 1 (5.3%) |
| Veronika Hood et al. [24] | mRNA vaccine (n = 115) | First dose: No side effects (66.5%), injection site pain 2 (13.6%), injection site redness 1 (5.3%), headache 1 (5.3%), fever 1 (5.3%) |
|                         | Viral-vector vaccine (n = 5)               | First dose: No side effects (66.5%), injection site pain 2 (13.6%), injection site redness 1 (5.3%), headache 1 (5.3%), fever 1 (5.3%) |
| Lu et al. [25]         | First dose of inactivated vaccine (n = 204)| First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                        | Second dose of inactivated vaccine (n = 139)|                                                                                         |
| Massoud et al. [26]    | First dose of mRNA vaccine (n = 15)       | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                        | Second dose of mRNA vaccine (n = 35)      | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
| Özdemir et al. [27]    | First dose of mRNA vaccine (n = 136)      | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                        | First dose of inactivated vaccine (n = 42) | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                        | Second dose of mRNA vaccine (n = 136)     | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                        | Second dose of inactivated vaccine (n = 42)| First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
| Wrede et al. [30]      | mRNA vaccine (n = 34)                      | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                         | Viral-vector vaccine (n = 18)              | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |
|                         | Unable to remember (n = 2)                | First dose: No side effects (88.2%), injection site pain 2 (2.6%), injection site swelling 1 (2.6%), injection site redness 1 (2.6%), fatigue 1 (2.6%), headache 1 (2.6%), fever 1 (2.6%) |

**Abbreviations:** COVID = coronavirus disease 2019.

### Table 4
Risk of bias of the cross-sectional studies assessed using AHRQ.

| Study                  | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | Score |
|------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|
| Li et al. [17]         | Y   | Y   | Y   | N   | N   | N   | Y   | Y   | N   | Y   | Y   | N   | 6     |
| Asadi et al. [22]      | Y   | Y   | Y   | Y   | N   | N   | N   | Y   | Y   | N   | Y   | N   | 6     |
| Clayton et al. [23]    | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |
| Hood et al. [24]       | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |
| Lu et al. [25]         | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |
| Massoud et al. [26]    | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |
| Özdemir et al. [27]    | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |
| Puteikis et al. [28]   | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |
| Qiao et al. [29]       | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |
| Wrede et al. [30]      | Y   | Y   | Y   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   | 6     |

**NOTE:** 1. Define the source of information (survey, record review). 2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications. 3. Indicate time period used for identifying patients. 4. Indicate whether or not subjects were consecutive if not population-based. 5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants. 6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements). 7. Explain any patient exclusions from analysis. 8. Describe how confounding was assessed and/or controlled. 9. If applicable, explain how missing data were handled in the analysis. 10. Summarize patient response rates and completeness of data collection. 11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.

**Abbreviations:** AHRQ = Agency for Healthcare Research and Quality; Y = Yes; N = No.
four out of 178 patients with epilepsy had more seizures than normal [27]. Notably, Clayton et al. [23] reported that three (20%) patients with Dravet syndrome experienced an increase in seizure frequency after the first dose of Oxford/AstraZeneca vaccine, whereas there was no increase in seizure frequency or duration after the second dose. Since different types of vaccines (i.e., mRNA vaccines, viral vector vaccines, and inactivated vaccines) have different principles for immunogenicity, whether COVID-19 vaccine types influence the seizure worsening in patients with epilepsy needs to be investigated in further studies.

A previous study showed that a considerable proportion (302 [54.2%]) of patients with epilepsy believed there were differences in safety and efficacy among different vaccines [29]. Concern about potential vaccine-related adverse effects is a critical factor influencing vaccination coverage and willingness. The currently available vaccines have been shown to be safe and tolerable in the general population. However, limited evidence of vaccination in patients with epilepsy might influence the attitudes of health workers, caregivers, and patients with epilepsy toward COVID-19 vaccination. Although the limited information in the included studies does not permit quantitative analysis, most reported adverse effects were self-limited mild to moderate. Moreover, adverse effects were rarely severe, suggesting a considerable safety profile of COVID-19 vaccines in patients with epilepsy. However, caution needs to be addressed because long-term evidence is still scarce; future studies with long-term follow-up are needed.

Social and educational factors like insufficient publicity and education, and lack of knowledge about vaccination might also account for a low vaccination coverage and willingness. Healthcare workers cannot give suggestive answers on whether or not to receive COVID-19 vaccination without adequate education and training. For example, Clayton et al. [23] showed that 27 (77%) caregivers did not receive any professional healthcare advice on COVID-19 vaccination in patients with epilepsy. Other factors may include education background, occupation, residence, and economic status. Comprehensive education programs are needed to improve the attitudes toward COVID-19 vaccination.

Our study has limitations. First, the survey-based nature of the included studies contributes to both measurement bias and selection bias. For example, administration of surveys on a cross-sectional basis inevitably introduces measurement bias through inaccurate reporting of vaccine-related adverse effects. Second, the survey tools in the included studies had not been validated. Future studies with well-validated survey tools are needed. Moreover, publication bias tests and subgroup analysis stratified by vaccine types and dosage were not performed due to the limited number of studies with insufficient information. Future larger sample sized studies with long follow-up are necessary to evaluate the safety and tolerability of COVID-19 vaccines among patients with epilepsy. Lastly, lack of a control group in most included studies contributes to both measurement bias and selection bias. Therefore, randomization or propensity scores are needed.

5. Conclusion

The present study suggests that the COVID-19 vaccination coverage and willingness were still low in patients with epilepsy. However, vaccination against COVID-19 appears to be well-tolerated and safe in patients with epilepsy, supporting a positive outlook toward vaccination in this population.

Acknowledgements

Not applicable.

Conflicts of interests statement

The authors declare that they have no conflict of interests.

Funding

None.

Ethics approval

The ethics approval was waived because this is a systemic review and meta-analysis.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Authors’ contributions

K.L. and H.D. designed the study. K.L., H.H., and S.F. drafted the manuscript and shared the first-author. K.L. and S.F. contributed to data extraction. K.L. and H.D. performed the statistical analysis. G.Z., K.F. and N.L. made the critical revision of the manuscript for important intellectual content. H.D had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.yebeh.2022.108822.

References

[1] Hopkins J. Johns Hopkins Coronavirus Resource Center. Https://coronavirus. Jhu.edu/map.Htm (2022, accessed 30 April 2022).
[2] Mahase E. Covid-19: Omicron and the need for boosters. BMJ 2021;375:n3079.
[3] Lopez Bernal J, Andrews N, Cower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta), Variant N Engl J Med 2021;385(7):585–94.
[4] Wolf ME, Luz B, Niehaus I, Bhogal P, Bäzner H, Henkes H. Thrombocytopoenia and intracranial venous sinus thrombosis after “COVID-19 vaccine AstraZeneca” exposure. J Clin Med 2021;10(8):1599.
[5] Krzywicka K, van de Munchhof A, Sánchez van Kammern M, Heldner MR, Jood K, Lindgren E, et al. Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination. Neurology. 2022 Feb 15;98(7):e759-e768.
[6] Waheed W, Carey ME, Tandan SR, Tandan R. Post COVID-19 vaccine small fiber neuropathy. Muscle Nerve 2021;64(1):E1–2.
[7] Márquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA, Guillian-Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology 2021;96(22):1052–4.
[8] Havla J, Schultz Y, Zimmermann H, Hohlfeld R, Danek A, Kümple T. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol 2022;269(3):1093–106.
[9] Khayat-Rhoei M, Bhattacharyya S, Katz J, Harrison D, Taudhid S, Bruso P, et al. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol 2022;269(3):1093–106.
[10] Faisser N, Richter D, Ceylan U, Schneider-Gold C, Gold R. COVID-19 mRNA vaccine induced rhombomylitis and fasciitis. J Neurol 2022;269:1774–5.
